| 股份代號: | 02256 | | --- | --- | | 上市法國名稱: | 和譽開曼有限量任公司 - B | | 日期(日 / 月 / 年): | 27/10/2025 - 27/11/2025 | | 如欲看按摺權益過知之內容,請於「有關事件的日期」欄按下有關連結 · | | | * 註解:(L)-好禽(S) - 淡禽(P)-可供僵出的股份 | | | WHE ARE COLLEGE . | 中移新疆新疆第三次国家公路 地址提倡的 第1 / 德国地址买谷路 加拿达国内幕 -- 林为福利公路沿岸区 北京赛乐站 大厦湖地的日期 保护比赛范围 | | Children to | ARS LEWICE FRANCE FERSES RATRACTS 4887798 | | | A M S C S T | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 份的目 | 原因 | | (跨金関上述* 註解) 狗股票權股 (日/月/年) 權益 | | | | | | | | | 份自分比 | | | | | | | | | ( % ) | | ...

Core Viewpoint - The stock of He Yu-B (02256) has seen a significant increase, with a rise of over 4% in the late trading session, currently up by 3.9% at HKD 14.13, with a trading volume of HKD 45.41 million [1] Group 1: Company Developments - He Yu announced that its subsidiary, He Yu Pharmaceutical, presented long-term efficacy, safety, and patient-reported outcome data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) at the CTOS 2025 conference [1] - The long-term analysis indicates that continuous treatment with pimicotinib can lead to sustained improvements in tumor response and further enhancements in patient-reported outcomes, including pain and function, while maintaining an acceptable safety profile [1] - The findings reinforce the long-term application potential of pimicotinib in suitable patients [1]

智通财经APP获悉，和誉-B(02256)尾盘涨超4%，截至发稿，涨3.9%，报14.13港元，成交额4541万港 元。 消息面上，和誉公布，其附属和誉医药在结缔组织肿瘤学会(CTOS)2025年会上以壁报形式，展示匹米 替尼(pimicotinib/ABSK021)治疗腱鞘巨细胞瘤(TGCT)患者的全球III期MANEUVER研究的长期疗效、安 全性及患者报告结果数据。 该长期分析显示，持续接受匹米替尼治疗可为TGCT患者在肿瘤缓解方面带来疗效持续提升与患者报告 结果(包括疼痛与功能)的进一步改善，同时维持可接受的安全性，强化匹米替尼在适合患者中的长期应 用潜力。 ...

和誉 20251119 摘要 FGFR 4 项目目前进展如何？ FGFR 4 项目在研发日提供的数据和进展超出预期。目前二线加丹药的注册性 临床试验已于今年（2025 年）6 月开始患者入组，进展比原计划更快。预计明 年（2026 年）此时将完成试验并获得 ORR 数据，以便向 CDE 递交 NDA 申请。 这意味着 FGFR 4 可能在 2027 年四季度至 2028 年上半年进入商业化状态。 此外，一线加 Combo FURTHER 研究方案已与 FDA 初步沟通完毕，计划明年 上半年确定方案并开展全球多中心 MRCT 试验。 匹米替尼预计 2026 年下半年在中美欧实现商业化，有望带来可持续现 金流。美国市场销售峰值预计 5-6 亿美元，欧洲 4-5 亿欧元，中国 10- 15 亿人民币，加拿大和日本市场也将贡献增量。 FGFR 4 项目二线加丹药注册性临床试验提前至 2025 年 6 月启动患者 入组，预计 2026 年完成试验并获得 ORR 数据，有望 2027 年四季度至 2028 年上半年商业化。一线加 Combo FURTHER 研究方案已与 FDA 初步沟通，计划明年上半年开展全球多中心 M ...

Group 1 - The core theme of the upcoming "10th Zhitong Financial Capital Market Annual Conference" is "Winning the Hong Kong Stock Surge: Bullish Outlook for 2026," focusing on the potential of Chinese assets amid a new technology-driven bull market [1] - The Hang Seng Index surged by 28% in a single quarter, while the Hang Seng Tech Index rebounded over 50% year-to-date, indicating a significant capital influx into undervalued Chinese assets [1] - The conference will feature prominent speakers, including economists and fund managers, who will discuss cross-border capital flows and relative valuation opportunities in the Hong Kong stock market [2] Group 2 - The afternoon session will focus on innovative pharmaceuticals, with companies like Deke Pharma and He Yu sharing insights on their latest clinical developments and commercialization strategies [3] - A diverse lineup of over 80 listed companies will participate in roadshows, providing investors with opportunities for in-depth discussions and identifying quality investment targets [4] Group 3 - The "3rd Overseas Fund Summit" will take place on December 4, featuring discussions on global capital allocation strategies and the impact of geopolitical shifts on investment [5] - The event will include four strategic roundtable discussions, addressing topics such as cognitive warfare and the mission of capital in a post-scarcity era [6] - The conference will conclude with the presentation of the New Intelligence Awards, showcasing the evolution of investment strategies from present to future [6] Group 4 - The event will continue in Hong Kong on December 5, maintaining a dual-city format that emphasizes the synergy between technological breakthroughs and global capital trends [6] - The conference aims to explore new patterns, tracks, and dividends arising from the new technological revolution, inviting participants to engage in high-level discussions [6]

Major Events - Shandong Xinhua Pharmaceutical Co., Ltd. received the approval notice for the listing application of fumaric acid vonoprazan chemical raw materials [1] - HeYue Pharmaceutical showcased long-term efficacy and safety data from the clinical III MANEUVER study of pitmiprazole at the CTOS 2025 conference [1] - China Software International partnered with Deep Open Hong and Yiswei Computing to build a new ecosystem for "open-source HarmonyOS + RISC-V" digital infrastructure [1] - China General Nuclear Power Corporation's Zhaoyuan Unit 1 is set to begin full construction [1] - Hengrui Medicine's fumaric acid teglutide injection received approval for clinical trials [1] - China National Nuclear Corporation signed an intention procurement agreement for cobalt-60 irradiation sources with the Brazilian National Nuclear Energy Commission [1] Operating Performance - China Railway Construction Corporation recently won several major projects with a total investment of 49.629 billion yuan [1] - Geely Automobile reported a net profit of 3.82 billion yuan for the third quarter, a year-on-year increase of 59% [1] - China Resources Power's subsidiary power plants achieved a cumulative electricity sales volume of 185 million megawatt-hours in the first ten months, a year-on-year increase of 6.5% [1] - Leap Motor reported a net profit of 150 million yuan for the third quarter, maintaining the top sales position among new force brands in China for eight consecutive months [1] - Huazhu Group's net profit attributable to shareholders for the third quarter was 1.5 billion yuan, a year-on-year growth of 15.4% [1] - Air China saw a year-on-year increase of 8.7% in passenger turnover in October [1] - China Eastern Airlines reported a year-on-year increase of 10.58% in passenger turnover in October [1]

Core Viewpoint - The announcement highlights the long-term efficacy and safety of pimicotinib in treating TGCT patients, reinforcing its potential for long-term application in suitable patients [1] Group 1: Company Information - The subsidiary Shanghai Heyu Biopharmaceutical Technology Co., Ltd. presented data at the CTOS 2025 conference regarding the global Phase III MANEUVER study of pimicotinib for TGCT patients [1] - The long-term analysis indicates that continuous treatment with pimicotinib leads to sustained improvements in tumor response and patient-reported outcomes, including pain and function [1] - The study emphasizes that the treatment maintains an acceptable safety profile, supporting the long-term use of pimicotinib in appropriate patients [1]

Core Viewpoint - The announcement highlights the long-term efficacy and safety of pimicotinib in treating TGCT patients, as presented at the CTOS 2025 conference, reinforcing its potential for long-term application in suitable patients [1] Group 1: Company Information - Shanghai Heyu Biopharmaceutical Technology Co., Ltd., a subsidiary of Heyu-B, showcased data from the global Phase III MANEUVER study on pimicotinib for TGCT patients [1] - The study results indicate that continuous treatment with pimicotinib leads to sustained improvements in tumor response and patient-reported outcomes, including pain and function [1] Group 2: Industry Insights - The findings from the MANEUVER study strengthen the position of pimicotinib in the treatment landscape for TGCT, suggesting a viable long-term treatment option for patients [1] - The acceptable safety profile maintained during the study supports the ongoing development and potential market introduction of pimicotinib for this indication [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 自願性公告 和譽醫藥於CTOS 2025年會展示匹米替尼臨床III期 MANEUVER研究長期療效和安全性數據 承董事會命 和譽開曼有限責任公司 徐耀昌博士 主席 上海，2025年11月17日 於本公告日期，本公司董事會包括執行董事徐耀昌博士、喻紅平博士及嵇靖博 士；以及獨立非執行董事孫飄揚博士、孫洪斌先生及徐海音女士。 1 和譽開曼有限責任公司（「本公司」，連同其附屬公司統稱「本集團」）謹此隨附新 聞稿，以告知本公司股東及潛在投資者，本公司之附屬公司上海和譽生物醫藥科 技有限公司（「和譽醫藥」）宣佈，其在結締組織腫瘤學會（「CTOS」）2025年會上以 壁報形式展示了匹米替尼(pimicotinib/ABSK021)治療腱鞘巨細胞瘤（「TGCT」）患 者的全球III期MANEU ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： USD 50,000 致：香港交易及結算所有限公司 公司名稱: 和譽開曼有限责任公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02256 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | ...